DE602004028739D1 - Metabolit von quetiapine - Google Patents

Metabolit von quetiapine

Info

Publication number
DE602004028739D1
DE602004028739D1 DE602004028739T DE602004028739T DE602004028739D1 DE 602004028739 D1 DE602004028739 D1 DE 602004028739D1 DE 602004028739 T DE602004028739 T DE 602004028739T DE 602004028739 T DE602004028739 T DE 602004028739T DE 602004028739 D1 DE602004028739 D1 DE 602004028739D1
Authority
DE
Germany
Prior art keywords
quetiapine
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004028739T
Other languages
English (en)
Inventor
Scott W Grimm
Helen R Winter
Patricia Davis
Raymond F Suckow
Jeffrey Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602004028739D1 publication Critical patent/DE602004028739D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004028739T 2003-07-02 2004-06-28 Metabolit von quetiapine Active DE602004028739D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
PCT/GB2004/002783 WO2005002586A1 (en) 2003-07-02 2004-06-28 Metabolite of quetiapine

Publications (1)

Publication Number Publication Date
DE602004028739D1 true DE602004028739D1 (de) 2010-09-30

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028739T Active DE602004028739D1 (de) 2003-07-02 2004-06-28 Metabolit von quetiapine

Country Status (20)

Country Link
US (1) US20050026900A1 (de)
EP (1) EP1644005B1 (de)
JP (1) JP2007516193A (de)
KR (1) KR20060082037A (de)
CN (1) CN1816339B (de)
AR (1) AR045004A1 (de)
AT (1) ATE477803T1 (de)
AU (1) AU2004253334A1 (de)
BR (1) BRPI0412127A (de)
CA (1) CA2531284A1 (de)
DE (1) DE602004028739D1 (de)
ES (1) ES2349091T3 (de)
IL (1) IL172616A0 (de)
IS (1) IS8283A (de)
MX (1) MXPA05013869A (de)
NO (1) NO20060556L (de)
RU (1) RU2005141060A (de)
TW (1) TW200509944A (de)
UY (1) UY28400A1 (de)
WO (1) WO2005002586A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2000141A1 (de) * 2002-03-20 2008-12-10 Teva Pharmaceutical Industries Ltd. Verfahren zur Herstellung von Kristalline Quetiapinhemifumarat
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
WO2006073360A1 (en) * 2005-01-07 2006-07-13 Astrazeneca Ab NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
US7687622B2 (en) * 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
CN101360724A (zh) * 2005-11-18 2009-02-04 阿斯利康公司 盐形式
WO2007062339A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Liquid formulations
WO2007062338A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
WO2008079839A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab Compounds and uses thereof
EP1951257A4 (de) * 2005-11-18 2008-11-05 Astrazeneca Ab Kristalline formen
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2008116144A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Methods of treating mood disorders
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
EP2120563A4 (de) * 2006-12-20 2011-04-27 Astrazeneca Ab Verbindungen und ihre verwendungen
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
WO2011082076A1 (en) 2009-12-31 2011-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US8900604B2 (en) 2010-03-11 2014-12-02 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用

Also Published As

Publication number Publication date
IL172616A0 (en) 2006-04-10
EP1644005A1 (de) 2006-04-12
EP1644005B1 (de) 2010-08-18
CA2531284A1 (en) 2005-01-13
JP2007516193A (ja) 2007-06-21
IS8283A (is) 2006-02-01
CN1816339A (zh) 2006-08-09
NO20060556L (no) 2006-04-03
KR20060082037A (ko) 2006-07-14
BRPI0412127A (pt) 2006-08-15
WO2005002586A1 (en) 2005-01-13
ES2349091T3 (es) 2010-12-27
TW200509944A (en) 2005-03-16
ATE477803T1 (de) 2010-09-15
AR045004A1 (es) 2005-10-12
AU2004253334A1 (en) 2005-01-13
WO2005002586A8 (en) 2006-02-09
RU2005141060A (ru) 2006-07-27
MXPA05013869A (es) 2006-02-28
US20050026900A1 (en) 2005-02-03
UY28400A1 (es) 2005-01-31
CN1816339B (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
ATE477803T1 (de) Metabolit von quetiapine
DE60309013D1 (de) Knoten
DE60321740D1 (de) Toner
DE60306080D1 (de) Toner
NO20043696L (no) Gamma-sekretaseinhibitorer
ITMI20041123A1 (it) Fissaggio
DK1472255T3 (da) Aza-arylpiperaziner
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
DE60321615D1 (de) Toner
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DE602004024640D1 (de) Reinigung von titantetrachlorid
ITMI20021327A1 (it) Nuove ossialchilpiperazine
ATE410417T1 (de) Kristallmodifikationen von triazinylaminostilbenen
ITMS20020001U1 (it) Help your self
ITMS20020001A1 (it) Help your self
UA9239S (uk) Комплект етикеток
UA7418S (uk) Комплект етикеток
UA9242S (uk) Комплект етикеток
UA8155S (uk) Комплект етикеток
UA7807S (uk) Комплект етикеток
UA8904S (uk) Комплект етикеток
UA9821S (uk) Комплект етикеток
UA8496S (uk) Комплект етикеток
UA6746S (uk) Кобза чотириструнна
FIU20020171U0 (fi) Puupalkki